Clinics in Liver Disease肝病临床综述
Clinics in Liver Disease(英文缩写 CLIN LIVER DIS),ISSN 1089-3261,eISSN 1557-8224,中文译名:肝病临床综述 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 6.265 | Q2 |
| 2022 | 5.100 | Q2 |
| 2023 | 2.900 | Q2 |
| 2024 | 4.100 | Q1 |
| 2025 | 2.900 | Q2 |
Clinics in Liver Disease 最新收录文献
-
1. Cholestatic Liver Disease Across the Life Span: A Primer for Clinicians.
PMID:日期:2026-08-01该文献暂无摘要。
-
2. Recurrence of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis after Liver Transplantation: Current Evidence and Clinical Implications.
PMID:日期:2026-08-01Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are progressive cholestatic autoimmune liver diseases, characterized by the destruction of intrahepatic and/or extrahepatic bile ducts, leading to cirrhosis and liver failure. They remain major indications for liver transplantation (LT), and together, PBC and PSC account for approximately 10% to 15% of LT in North America and Europe. While clinical outcomes are generally favorable after LT, the recurrence of PBC and PSC remains a significant challenge. Reported recurrence rates of PBC and PSC after LT range from 17% to 46% and 10% to 37% of recipients, respectively.
-
3. Perihilar Cholangiocarcinoma in Primary Sclerosing Cholangitis.
PMID:日期:2026-08-01This clinical review details the current approach for the detection and management of perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis. It summarizes the contemporary understanding of epidemiology, risk factors, current diagnostic tools and their limitations, and highlights emerging biomarkers currently under investigation. This review also discusses the role of neoadjuvant chemoradiation followed by liver transplantation as a potentially curative treatment.
-
4. Immunoglobulin G4-Related Sclerosing Cholangitis: A Review.
PMID:日期:2026-08-01Immunoglobulin G4-related sclerosing cholangitis (IgG4-SC) is a steroid-responsive biliary manifestation of IgG4-related disease, commonly associated with type I autoimmune pancreatitis and can mimic primary SC or cholangiocarcinoma. Diagnosis relies on the histology, imaging, serology, other-organ involvement, and response to therapy criteria. First-line therapy is corticosteroids; relapsing or refractory disease requires steroid-sparing immunomodulators or B cell-targeted therapy (rituximab).
-
5. "Overlap" Syndromes in Autoimmune Liver Disease: Definitions, Clinical Challenges and Future Directions.
PMID:日期:2026-08-01Autoimmune liver diseases, including autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis, are rare chronic conditions characterized by immune-mediated hepatobiliary injury. While traditionally viewed as distinct entities, they exist along a continuous spectrum, manifesting in some cases as "overlap" or "variant" syndromes. These variants are considered phenotypic variations of shared pathways rather than unique diseases. The rarity of these conditions and an incomplete understanding of their underlying pathophysiology have prevented standardized definitions, and ultimately hinder the development of robust, evidence-based clinical protocols for these patient populations. This review aims to offer a pragmatic clinical approach to these complex cases.
-
6. Primary Sclerosing Cholangitis.
PMID:日期:2026-08-01Sclerosing cholangitis encompasses a spectrum of disorders, characterised by multi-level biliary stricturing. The prefix 'primary' refers to the commonest form, PSC. Although rare, incidence and prevalence are rising, which when coupled with the absence of life-prolonging therapy has resulted in PSC being one of the lead indications for liver transplantation. Herein, we present a clinically focussed overview of PSC epidemiology, natural history, and nuances surrounding monitoring and surveillance. We go on to discuss how gut inflammation may affect the clinical course that patients experience, whilst giving way to bile acid therapies, molecularly targeted antifibrotics, and a bevy of microbiome-based interventions.
-
7. Primary Biliary Cholangitis.
7. 原发性胆汁性胆管炎PMID:日期:2026-08-01Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by persistent cholestasis and progressive fibrosis. Diagnosis relies on cholestatic biochemistry with AMA or PBC-specific antinuclear antibodies positivity; biopsy is reserved for atypical cases. Ursodeoxycholic acid (UDCA) remains first-line, with on treatment biochemical response predicting long-term prognosis. Symptom management-particularly for pruritus, fatigue, and sicca-is crucial to address patient's quality of life. Long-term care includes surveillance for treatment response, development of fibrosis, portal hypertension, bone disease, and hepatocellular carcinoma. Liver transplantation (LT) remains definitive for end-stage or refractory disease, with post-LT UDCA recommended to reduce its recurrence.
-
8. Intrahepatic Cholestasis of Pregnancy.
8. 妊娠期肝内胆汁淤积症PMID:日期:2026-08-01Intrahepatic cholestasis of pregnancy is the most common liver disorder induced by pregnancy. It is characterized by pruritus, with onset typically at the end of the second trimester. Etiology is likely related to effects of estrogen and progesterone. It is a diagnosis of exclusion, and underlying cholestatic conditions that are potentially unmasked by pregnancy need to be considered, especially if onset in pregnancy is early, or if symptoms and bile acid elevation are particularly severe. The spectrum of disease varies from mild to clinically morbid pruritus with associated fetal morbidity and even mortality.
-
9. Genetic Cholestasis Syndromes.
9. 遗传性胆汁淤积综合征PMID:日期:2026-08-01This article focuses on common genetic cholestatic liver syndromes, looking at genotype-phenotype correlations in conditions such as progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis disorders and cholangiopathies. It discusses how molecular classification informs prognosis, malignancy risk and therapeutic response. This review also discusses current and emerging therapies, notably ileal bile acid transport inhibitors and their use in PFIC and Alagille syndrome.
-
10. Biliary Atresia: A Focus on the Patient Journey from Diagnosis to Transplant.
PMID:日期:2026-08-01Biliary atresia is a complex cholangiopathy of infancy characterized by extrahepatic biliary obstruction and progressive intrahepatic fibroinflammatory injury. It remains the leading indication for liver transplant in children without any disease-modifying medical therapies. Herein the authors review updated literature relevant to the patient journey from diagnosis through end-stage liver disease up to liver transplantation. They focus on the burden of disease throughout this course including a focus on actionable areas of potential future study that could help transform patient care.